1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018,68(6):394-424.
2.Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al.Breast cancer.Nat Rev Dis Primers. 2019 Sep 23;5(1):66.
3.Velasco-Velázquez MA, Popov VM, Lisanti MP, Pestell RG. The role of breast cancer stem cells in metastasis and therapeutic implications.Am J Pathol. 2011 Jul;179(1):2-11.
4.Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011;64(11):937–46.
5.Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer.2013;13:727–38.
6.Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR, et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis. (2011) 32:650–8.
7.Vásquez-Bochm LX, Velázquez-Paniagua M, Castro-Vázquez SS, Guerrero-Rodríguez SL, Mondragon-Peralta A, De La Fuente-Granada M, et al. Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug . Pharmacol Rep. 2019 Jun;71(3):535-544.
8.Yin R, Li T, Tian JX, Xi P, Liu RH.Ursolic acid, potential anticancer compound for breast cancer therapy. Crit Rev Food Sci Nutr. 2018 Mar 4;58(4):568-574.
9.Baricevic D1, Sosa S, Della Loggia R, Tubaro A, Simonovska B, Krasna A, et al.Topical anti-inflammatory activity of Salvia officinalis L. leaves: the relevance of ursolic acid.J Ethnopharmacol. 2001 May;75(2-3):125-32.
10.Shanmugam MK1, Nguyen AH, Kumar AP, Tan BK, Sethi G. Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: potential role in prevention and therapy of cancer. Cancer Lett. 2012 Jul 28;320(2):158-70.
11.Woźniak Ł, Skąpska S, Marszałek K.Ursolic Acid--A Pentacyclic Triterpenoid with a Wide Spectrum of Pharmacological Activities.Molecules. 2015 Nov 19;20(11):20614-41.
12.Seo DY, Lee SR, Heo JW, No MH, Rhee BD, Ko KS, et al.Ursolic acid in health and disease.Korean J Physiol Pharmacol. 2018 May;22(3):235-248.
13.Jaman MS, Sayeed MA. Ellagic acid, sulforaphane, and ursolic acid in the prevention and therapy of breast cancer: current evidence and future perspectives. Breast Cancer. 2018 Sep;25(5):517-528.
14.Ko EY, Moon A.Natural Products for Chemoprevention of Breast Cancer. J Cancer Prev. 2015 Dec;20(4):223-31.
15.Shan JZ, Xuan YY, Ruan SQ, Sun M.Proliferation-inhibiting and apoptosis-inducing effects of ursolic acid and oleanolic acid on multi-drug resistance cancer cells in vitro. Chin J Integr Med. 2011 Aug;17(8):607-11.
16.K.H. Kim, H.S. Seo, H.S. Choi, I. Choi, Y.C. Shin, S.G. Ko. Induction of apoptotic cell death by ursolic acid through mitochondrial death pathway and extrinsic death receptor pathway in MDA-MB-231 cells. Arch Pharm Res. 2011 Aug;34(8):1363-72.
17.Shishodia S, Majumdar S, Banerjee S, Aggarwal BB. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1.Cancer Res. 2003 Aug 1;63(15):4375-83.
18.M.K. Shanmugam, X. Dai, A.P. Kumar, B.K. Tan, G. Sethi, A. Bishayee. Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. Biochem Pharmacol. 2013 Jun 1;85(11):1579-87.
19.Shao G, Zhou H, Zhang Q, Jin Y, Fu C. Advancements of Annexin A1 in inflammation and tumorigenesis.Onco Targets Ther. 2019 Apr 30;12:3245-3254.
20.Rescher U, Gerke V. Annexins – unique membrane binding proteins with diverse functions. J Cell Sci. 2004;117:2631–9.
21.Futter CE, White IJ. Annexins and endocytosis. Traffic. 2007;8:951–8.
22.McArthur S, Yazid S, Christian H, Sirha R, Flower R, Buckingham J, et al.Annexin A1 regulates hormone exocytosis through a mechanism involving actin reorganization. FASEB J. 2009;23:4000–10.
23.Mu D, Gao Z, Guo H, Zhou G, Sun B. Sodium butyrate induces growth inhibition and apoptosis in human prostate cancer DU145 cells by upregulation of the expression of annexin A1. PLoS One. 2013 Sep 23;8(9):e74922.
24.Bizzarro V, Fontanella B, Franceschelli S, Pirozzi M, Christian H, Parente L, et al. Role of Annexin A1 in mouse myoblast cell differentiation. J Cell Physiol. 2010;224:757–65.
25.Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol. 2008 Oct;216(2):131-40.
26.Guo C, Liu S, Sun MZ. Potential role of ANXA1 in cancer. Future Oncol.2013;9:1773–93.
27.Yi M, Schnitzer JE. Impaired tumor growth, metastasis, angiogenesis and wound healing in annexin A1-null mice. Proc Natl Acad Sci U S.2009;106:17886–91.
28.R. Biaoxue, C. Xiguang, Y. Shuanying, Annexin A1 in malignant tumors: current opinions and controversies.Int J Biol Markers. 2014 Mar 24;29(1):e8-20.
29.Crabtree JS, Miele L. Breast Cancer Stem Cells.Biomedicines. 2018 Jul 17;6(3).
30.Shao G, Zhou H, Zhang Q, Jin Y, Fu C. Advancements of Annexin A1 in inflammation and tumorigenesis. Onco Targets Ther. 2019 Apr 30;12:3245-3254.
31.Scheau C, Badarau IA, Costache R, Caruntu C, Mihai GL, Didilescu AC, et al. The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma.Anal Cell Pathol (Amst). 2019 Nov 26;2019:9423907
32.Blagodatski A, Poteryaev D, Katanaev VL.Targeting the Wnt pathways for therapies. Mol Cell Ther. 2014 Sep 11;2:28.
33.Many AM, Brown AM. Both canonical and non-canonical Wnt signaling independently promote stem cell growth in mammospheres. PLoS One. 2014 Jul 14;9(7).
34.H.P. Sinn, H. Kreipe, A brief overview of the WHO classification of Breasttumors, 4th edition, focusing on issues and updates from the 3rd edition.Breast Care (Basel). 2013 May;8(2):149-54.
35.T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, et al. Gene expressionpatterns of breast carcinomas distinguish tumor subclasses with clinicalimplications. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74.
36.C.M. Perou, T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52.
37.Tu Y, Johnstone CN, Stewart AG. Annexin A1 influences in breast cancer: Controversies on contributions to tumour, host and immunoediting processes. Pharmacol Res. 2017 May;119:278-288.
38.Sheikh MH, Solito E. Annexin A1: Uncovering the Many Talents of an Old Protein. Int J Mol Sci. 2018 Mar 31;19(4).
39.Patel S, Alam A, Pant R, Chattopadhyay S. Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel TherapeuticInsights. Front Immunol. 2019 Dec 16;10:2872.
40.Minashima T, Kirsch T. Annexin A6 regulates catabolic events in articular chondrocytes via the modulation of NF-κB and Wnt/ß-catenin signaling. PLoS One. 2018 May 17;13(5).
41.Rubinstein MR, Baik JE, Lagana SM, Han RP, Raab WJ, Sahoo D, et al.Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1.EMBO Rep. 2019 Apr;20(4).
42.de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J, et al. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6340-5.
43.M.A. Huber, N. Kraut, H. Beug. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005 Oct;17(5):548-58.
44.Y. Wang, B.P. Zhou. Epithelial-mesenchymal transition in breast cancer progression and metastasis.Chin J Cancer. 2011 Sep;30(9):603-11.